1. |
Baysal-Kirac L, Tuzun E, Altindag E, et al. Are there any specific EEG findings in autoimmune epilepsies. Clinical EEG & Neuroscience, 2016, 47: 224-234.
|
2. |
Ong M S, Kohane I S, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurology, 2014, 71(5): 569.
|
3. |
Matin N, Tabatabaie O, Falsaperla R, et al. Epilepsy and innate immune system: a possible immunogenic predisposition and related therapeutic implications. Hum Vaccin Immunother, 2015, 11: 2021-2029.
|
4. |
Geis C, Planagumà J, Carreño M, et al. Autoimmune seizures and epilepsy. J Clin Invest, 2019, 129(3): 926-940.
|
5. |
Titulaer MJ, McCracken L, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol, 2013, 12(2): 157-165.
|
6. |
Sonderen AV, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology, 2016, 87(14): 1449.
|
7. |
Nicolas, Gaspard, Brandon P, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology, 2015, 3, 85(18): 1604-1613.
|
8. |
Steriade C, Britton J, Dale R C, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia, 2020, 61(7): 1341-1351.
|
9. |
Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurology, 2008, 7(12): 1074-1075.
|
10. |
Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol, 2018, 83(1): 166-177.
|
11. |
Graus F, Tiulaer MJ et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology, 2016, 15: 391-401.
|
12. |
曹笃, 张丽娟, 郭秀明, 等. 自身免疫性脑炎临床表现与MRI特征分析. 中国神经精神疾病杂志, 2017, 43(6): 341-345.
|
13. |
Lai M, Peng X, Hughes E, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol, 2010, 9(1): 67-76.
|
14. |
Josep D, Francesc G, Alberto V, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain A Journal of Neurology, 2004, 127(pt 8): 1831.
|
15. |
Celicanin M, Blaabjerg M, Maersk-Moller C, et al. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study. Eur J Neurol, 2017, 24(8): 999-1005.
|
16. |
Shen CH, Fang GL, et al. Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis. Annals of Clinical and Translational Neurology, 2020, 7(8): 1392-1399.
|
17. |
Aurélien, Viaccoz, Virginie, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology, 2014, 82(7): 556-563.
|
18. |
Titulaer M J, Dalmau J. Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. Neurology, 2014, 82(7): 550-551.
|
19. |
Liu X, Yan B, Wang R, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia, 2017, 58(12): 2104-2111.
|
20. |
Weishuai Li, Si W, Qingping M, et al. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study. BMC Neurology, 2018, 18(1): 96.
|
21. |
Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins Lgi1 and Caspr2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain, 2010, 133(9): 2734-2748.
|
22. |
Amer, Syed, Shah, et al. Refractory status epilepticus from NMDA receptor encephalitis successfully treated with an adjunctive ketogenic diet. Annals of Indian Academy of Neurology, 2015, 18(2): 256-7.
|
23. |
Kadoya M, Onoue H, Kadoya A, et al. Refractory status epilepticus caused by anti-NMDA receptor encephalitis that markedly improved following combination therapy with rituximab and cyclophosphamide. Internal Medicine, 2015, 54(2): 209.
|
24. |
De Bruijn MAAM, Van Sonderen A, Van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology, 2019, 92(19): e2185-e2196.
|